Compare Delta Air Lines, Inc. (DAL) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Delta Air Lines, Inc. vs Sanofi SA — how do they compare? Delta Air Lines, Inc. trades at $82.11 (market cap $54.02B), while Sanofi SA trades at $40.04 (market cap $95.18B). The key difference: Sanofi SA is the larger of the two by market cap, and Sanofi SA pays the higher dividend (6.01%). Which is the better fit depends on your goals — on Pluang, investors hold Delta Air Lines, Inc. for 97 Days and Sanofi SA for 94 Days on average.
| DAL | SNY | |
|---|---|---|
Market Cap | $54.02B | $95.18B |
Volume | 9,632,845 | 2,995,646 |
Sector | Industrials | Health |
52-Week High | $93.66 | $52.34 |
52-Week Low | $55.65 | $39.51 |
Typical Hold Time | 97 Days | 94 Days |
Enterprise Value | $69.34B | $114.48B |
Dividend Yield | 1.05% | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Delta Air Lines (DAL) trades at $82.17, down 0.96% on the day, with a bearish technical signal. The stock shows strong fundamentals with a P/E of 13.62 and net income margin of 5.78%, supported by three consecutive quarterly earnings beats before a recent Q3 miss. Revenue growth is steady, reaching $63.36B in 2025. Analyst sentiment remains overwhelmingly positive with an 82.22% buy rating and a consensus price target of $103.36, indicating significant upside potential.
The outlook for DAL is favorable due to robust analyst support and improving cash flows, but risks include fuel cost volatility and competitive pressures. The stock's current price near support at $81 presents a potential entry point, though macroeconomic factors and execution on growth initiatives will be critical for sustained performance.
Sanofi (SNY) trades at $40.07, down 0.32% on the day, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.21 exceeding the $1.10 estimate. Revenue for 2025 reached $46.72 billion, with a net income margin of 16.72%. Recent news highlights a significant $8 billion immunology alliance expansion with Regeneron, signaling strategic growth initiatives.
The outlook is mixed; solid profitability and a strategic partnership provide upside potential, but a projected net income decline to $4.0 billion in 2026 and bearish technical indicators pose risks. Analyst sentiment is cautiously optimistic with a 44% buy rating, though investors should monitor execution of new collaborations and patent expiration impacts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Delta Air Lines, Inc.
Atlanta-based Delta Air Lines is one of the world's largest airlines, with a network of over 300 destinations in more than 50 countries. Delta operates a hub-and-spoke system network, where it gathers and distributes passengers across the globe through key locations such as Atlanta, New York, Salt Lake City, Detroit, Seattle, and Minneapolis-St. Paul. Delta's sale of frequent flier miles, particularly to American Express, is a major driver of the firm's profits.
Read more on DAL →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
